See more : Gladstone Commercial Corporation (0IVQ.L) Income Statement Analysis – Financial Results
Complete financial analysis of Allergy Therapeutics plc (AGYTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Allergy Therapeutics plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Hayward Holdings, Inc. (HAYW) Income Statement Analysis – Financial Results
- Fox River Resources Corporation (FXRVF) Income Statement Analysis – Financial Results
- Australis Capital Inc. (AUSAF) Income Statement Analysis – Financial Results
- ProbeLeader Co., Ltd. (5246.TWO) Income Statement Analysis – Financial Results
- Sanxiang Impression Co., Ltd. (000863.SZ) Income Statement Analysis – Financial Results
Allergy Therapeutics plc (AGYTF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.allergytherapeutics.com
About Allergy Therapeutics plc
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.20M | 59.59M | 72.77M | 84.33M | 78.20M | 73.72M | 68.35M | 64.14M | 48.51M | 43.23M | 41.96M | 39.28M | 41.28M | 41.55M | 40.75M | 37.76M | 31.02M | 25.74M | 23.56M | 20.61M | 18.00M | 17.33M | 15.14M |
| Cost of Revenue | 25.46M | 26.34M | 23.26M | 22.11M | 20.20M | 18.38M | 17.01M | 16.77M | 14.07M | 12.18M | 11.95M | 11.95M | 13.67M | 13.22M | 11.16M | 13.56M | 10.87M | 10.07M | 6.51M | 4.85M | 5.51M | 5.33M | 5.27M |
| Gross Profit | 29.74M | 33.25M | 49.51M | 62.23M | 58.00M | 55.34M | 51.33M | 47.37M | 34.44M | 31.05M | 30.00M | 27.33M | 27.61M | 28.33M | 29.59M | 24.19M | 20.16M | 15.67M | 17.05M | 15.75M | 12.49M | 12.00M | 9.87M |
| Gross Profit Ratio | 53.87% | 55.79% | 68.03% | 73.79% | 74.17% | 75.07% | 75.11% | 73.85% | 71.00% | 71.83% | 71.51% | 69.57% | 66.88% | 68.18% | 72.60% | 64.08% | 64.98% | 60.89% | 72.35% | 76.45% | 69.37% | 69.26% | 65.18% |
| Research & Development | 22.90M | 20.12M | 15.66M | 12.89M | 5.85M | 6.95M | 16.02M | 9.30M | 16.22M | 3.12M | 2.96M | 2.54M | 2.10M | 1.67M | 2.21M | 5.30M | 16.30M | 25.34M | 9.56M | 5.62M | 451.00K | 527.00K | 2.54M |
| General & Administrative | 22.79M | 25.18M | 20.83M | 20.67M | 19.63M | 17.60M | 15.54M | 13.78M | 10.09M | 10.22M | 7.99M | 7.85M | 15.18M | -8.29M | -6.03M | -14.74M | -12.71M | -11.14M | -6.81M | -4.96M | -2.23M | 0.00 | 0.00 |
| Selling & Marketing | 19.59M | 23.71M | 26.00M | 25.20M | 24.85M | 27.00M | 27.13M | 26.89M | 20.22M | 17.06M | 17.92M | 16.28M | 17.88M | 17.52M | 16.14M | 14.89M | 12.85M | 11.31M | 9.83M | 8.01M | 6.57M | 0.00 | 0.00 |
| SG&A | 42.38M | 48.88M | 46.83M | 45.87M | 44.48M | 44.59M | 42.68M | 40.67M | 30.32M | 27.28M | 25.91M | 24.12M | 33.06M | 9.23M | 10.12M | 158.00K | 147.00K | 169.00K | 3.03M | 3.05M | 4.34M | 0.00 | 0.00 |
| Other Expenses | -287.00K | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -154.00K | -171.00K | -191.00K | 0.00 | 0.00 | 0.00 | -196.00K | -193.00K | 3.37M | 367.00K | 31.00K | -350.00K | -262.00K | -34.00K | 0.00 | 0.00 |
| Operating Expenses | 64.99M | 72.90M | 61.75M | 58.19M | 49.69M | 50.95M | 58.06M | 49.26M | 46.39M | 30.33M | 28.80M | 26.66M | 35.16M | 28.39M | 28.01M | 32.68M | 44.71M | 50.92M | 24.80M | 18.95M | 10.93M | 13.57M | 14.07M |
| Cost & Expenses | 90.46M | 99.24M | 85.01M | 80.30M | 69.90M | 69.33M | 75.08M | 66.03M | 60.46M | 42.51M | 40.75M | 38.61M | 48.83M | 41.62M | 39.17M | 46.25M | 55.58M | 60.99M | 31.31M | 23.81M | 16.45M | 18.90M | 19.34M |
| Interest Income | 285.00K | 329.00K | 257.00K | 117.00K | 266.00K | 103.00K | 154.00K | 151.00K | 180.00K | 147.00K | 170.00K | 19.00K | 5.00K | 2.00K | 9.00K | 30.00K | 201.00K | 647.00K | 545.00K | 531.00K | 60.00K | 33.00K | 24.00K |
| Interest Expense | 4.11M | 2.44M | 669.00K | 491.00K | 504.00K | 201.00K | 320.00K | 225.00K | 293.00K | 218.00K | 308.00K | 404.00K | 457.00K | 1.54M | 1.79M | 3.24M | 1.97M | 131.00K | 4.00K | 42.00K | 26.00K | 39.00K | 545.00K |
| Depreciation & Amortization | 4.32M | 4.22M | 4.17M | 4.13M | 3.91M | 2.09M | 2.02M | 1.94M | 1.67M | 1.29M | 1.29M | 1.34M | 1.89M | 1.70M | 1.43M | 1.32M | 1.16M | 955.00K | 1.12M | 884.00K | 319.00K | 944.00K | 1.92M |
| EBITDA | -30.74M | -35.10M | -7.82M | 8.28M | 12.49M | 6.58M | -4.56M | 191.00K | -10.56M | 2.17M | 2.68M | 2.03M | 2.99M | 727.00K | 3.10M | -6.89M | -17.11M | -24.67M | -5.38M | -1.00M | 1.94M | 5.24M | -2.31M |
| EBITDA Ratio | -55.69% | -58.91% | -10.75% | 9.82% | 15.97% | 8.93% | -6.67% | 0.30% | -20.83% | 5.01% | 6.35% | 5.17% | 7.24% | 0.70% | 7.19% | -15.11% | -55.17% | -95.76% | -21.40% | -6.11% | 10.75% | 13.49% | -14.93% |
| Operating Income | -35.26M | -39.65M | -12.25M | 4.03M | 8.31M | 4.39M | -6.73M | -1.90M | -11.95M | 725.00K | 1.21M | 668.00K | 1.09M | 115.00K | 1.46M | 5.10M | 15.59M | 26.28M | 6.71M | 2.42M | 1.56M | 1.39M | 4.25M |
| Operating Income Ratio | -63.87% | -66.55% | -16.83% | 4.78% | 10.62% | 5.96% | -9.85% | -2.96% | -24.64% | 1.68% | 2.88% | 1.70% | 2.65% | 0.28% | 3.57% | 13.52% | 50.26% | 102.07% | 28.50% | 11.73% | 8.64% | 8.04% | 28.08% |
| Total Other Income/Expenses | -3.91M | -2.11M | -412.00K | -374.00K | -238.00K | -98.00K | -166.00K | -74.00K | -113.00K | -71.00K | -125.00K | -139.00K | -452.00K | -2.43M | -1.57M | -16.54M | -35.84M | -52.03M | -12.89M | -4.61M | 34.00K | 2.87M | -9.02M |
| Income Before Tax | -39.17M | -41.77M | -12.66M | 3.66M | 8.07M | 4.29M | -6.90M | -1.97M | -12.06M | 654.00K | 1.08M | 432.00K | 640.00K | -2.31M | -116.00K | -11.44M | -20.24M | -25.76M | -6.17M | -2.19M | 1.59M | 4.26M | -4.77M |
| Income Before Tax Ratio | -70.95% | -70.09% | -17.39% | 4.34% | 10.32% | 5.82% | -10.09% | -3.07% | -24.87% | 1.51% | 2.58% | 1.10% | 1.55% | -5.57% | -0.28% | -30.29% | -65.26% | -100.07% | -26.20% | -10.63% | 8.83% | 24.58% | -31.52% |
| Income Tax Expense | 1.05M | 1.31M | 1.12M | 771.00K | 1.01M | 826.00K | 637.00K | 511.00K | 1.01M | 546.00K | 343.00K | -104.00K | -183.00K | 349.00K | -702.00K | 326.00K | 53.00K | -2.50M | -12.87M | -4.56M | 372.00K | -916.00K | -109.00K |
| Net Income | -40.22M | -43.07M | -13.78M | 2.89M | 7.06M | 3.47M | -7.53M | -2.48M | -13.07M | 108.00K | 741.00K | 633.00K | 823.00K | -2.66M | 586.00K | -11.76M | -20.30M | -23.26M | -6.17M | -2.19M | 1.22M | 5.18M | -4.66M |
| Net Income Ratio | -72.86% | -72.28% | -18.93% | 3.42% | 9.03% | 4.70% | -11.02% | -3.87% | -26.95% | 0.25% | 1.77% | 1.61% | 1.99% | -6.41% | 1.44% | -31.16% | -65.43% | -90.34% | -26.20% | -10.63% | 6.77% | 29.87% | -30.80% |
| EPS | 0.00 | -0.06 | -0.01 | 0.00 | 0.01 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.14 | -0.25 | -0.28 | -0.09 | -0.04 | 0.03 | 0.08 | -0.07 |
| EPS Diluted | 0.00 | -0.06 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.14 | -0.25 | -0.28 | -0.09 | -0.04 | 0.03 | 0.08 | -0.07 |
| Weighted Avg Shares Out | 0.00 | 669.84M | 1.40B | 1.39B | 1.38B | 1.37B | 595.10M | 592.19M | 570.34M | 475.20M | 451.54M | 408.39M | 326.80M | 310.76M | 293.14M | 81.99M | 81.95M | 81.95M | 66.12M | 57.47M | 40.94M | 62.95M | 62.95M |
| Weighted Avg Shares Out (Dil) | 0.00 | 670.36M | 1.40B | 1.47B | 1.46B | 1.45B | 595.10M | 592.19M | 570.34M | 498.24M | 471.51M | 427.02M | 340.05M | 323.35M | 305.58M | 81.99M | 81.95M | 81.95M | 66.12M | 57.47M | 49.29M | 62.95M | 62.95M |
Allergy Therapeutics PLC new product wins German gong
Allergy Therapeutics PLC said ImmunoBON, the company's protein-based oral treatment, has been voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation Awards in Germany. The accolade was given after seeking the views of 700 doctors, 100 pharmacists...
Allergy Therapeutics hails encouraging secondary endpoint results from peanut allergy vaccine study
Allergy Therapeutics PLC (AIM:AGY, FRA:HHU) (AIM:AGY) announced encouraging secondary endpoint results from a study of its short-course peanut allergy vaccine candidate “VLP Peanut”. The secondary endpoint results from the ex-vivo biomarker study VLP001 demonstrated a reduced IgE binding capacity to B...
Allergy Therapeutics hails encouraging secondary endpoints results from peanut allergy vaccine study
Allergy Therapeutics PLC (AIM:AGY) announced encouraging secondary endpoint results from a study of its short-course peanut allergy vaccine candidate “VLP Peanut”. The secondary endpoint results from the ex-vivo biomarker study VLP001 demonstrated a reduced IgE binding capacity to B cells of...
Allergy Therapeutics' peanut vaccine study further de-risks programme says broker
Allergy Therapeutics PLC's study evaluating biomarkers from peanut-allergic patients' blood samples using its VLP Peanut vaccine candidate confirm its hypoallergic potential and should strengthen the company's Phase I study IND application to the FDA in late 2021, says finnCap. While...
Allergy Therapeutics announces successful primary outcome of VLP Peanut 001 study
Allergy Therapeutics PLC has announced a favourable outcome of a test of its peanut allergy vaccine candidate, “VLP Peanut”. The study, which took place at Imperial College London, evaluated the group's short-course VLP (virus-like particle) Peanut and aimed to demonstrate...
Allergy Therapeutics trading ahead of expectations
With our strong cash position, successful core products and exciting R&D pipeline, we look forward to the future with confidence CEO Manuel Llobet What the company does As the name suggests, Allergy Therapeutics PLC (LON:AGY), which is headquartered in Worthing,...
Allergy Therapeutics looks forward to key hay fever trial
With our strong cash position, successful core products and exciting R&D pipeline, we look forward to the future with confidence CEO Manuel Llobet What the company does As the name suggests, Allergy Therapeutics PLC (LON:AGY), which is headquartered in Worthing,...
Allergy Therapeutics sees revenue and operating profit ahead of expectations
Allergy Therapeutics PLC (LON:AGY) fleshed out June's trading statement in which it said operating profit would be well ahead of expectations. In the latest update, it told investors revenues would also beat forecasts.
Allergy Therapeutics sees revenues, operating profit ahead of expectations
Allergy Therapeutics PLC (LON:AGY) fleshed out June's trading statement in which it said operating profit would be well ahead of expectations. In the latest update, it told investors revenues would also beat forecasts.
Allergy Therapeutics provides further guidance after a strong year, sees revenues ahead
Allergy Therapeutics PLC (LON:AGY) fleshed out June's trading statement in which it said operating profit would be well ahead of expectations. In the latest update, it told investors revenues would also beat forecasts.
Source: https://incomestatements.info
Category: Stock Reports